Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 68Terminated 8Unknown 3Withdrawn 2Active not recruiting 2Recruiting 1Available 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Transitional Cell 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × tipifarnib × Clear all
NCT02535650 2022-03-08

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Samsung Medical Center

Phase 2 Unknown
19 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT00510939 2009-08-14

HEMOS AML 0106

University of Bologna

Phase 2 Unknown
72 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00006199 2005-06-24

Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)

National Center for Research Resources (NCRR)

Phase 1 Unknown
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡